Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 221

1.

Evidence for anti-VEGF treatment of diabetic macular edema.

Bandello F, Berchicci L, La Spina C, Battaglia Parodi M, Iacono P.

Ophthalmic Res. 2012;48 Suppl 1:16-20. doi: 10.1159/000339843. Epub 2012 Aug 21. Review.

PMID:
22907145
2.

Antivascular endothelial growth factor in diabetic retinopathy.

Iacono P, Battaglia Parodi M, Bandello F.

Dev Ophthalmol. 2010;46:39-53. doi: 10.1159/000320008. Epub 2010 Aug 10.

PMID:
20703031
3.

Diabetic macular edema.

Lang GE.

Ophthalmologica. 2012;227 Suppl 1:21-9. doi: 10.1159/000337156. Epub 2012 Apr 24. Review.

PMID:
22517122
4.
5.

Current intravitreal pharmacologic therapies for diabetic macular edema.

Colucciello M.

Postgrad Med. 2015 Aug;127(6):640-53. doi: 10.1080/00325481.2015.1052523. Epub 2015 Jun 3. Review.

PMID:
26036708
6.

Anti-VEGF for the management of diabetic macular edema.

Stefanini FR, Badaró E, Falabella P, Koss M, Farah ME, Maia M.

J Immunol Res. 2014;2014:632307. doi: 10.1155/2014/632307. Epub 2014 Feb 5. Review.

7.

Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.

Chong V.

Ophthalmologica. 2012;227 Suppl 1:2-10. doi: 10.1159/000337152. Epub 2012 Apr 24. Review.

PMID:
22517120
8.

[From scientific evidence to clinical practice: treatment protocols for diabetic macular edema].

López-Gálvez MI, García-Campos JM.

Arch Soc Esp Oftalmol. 2012 Dec;87 Suppl 1:38-45. Review. Spanish.

PMID:
24278988
9.

Update on nonsurgical therapy for diabetic macular edema.

Witkin AJ, Brown GC.

Curr Opin Ophthalmol. 2011 May;22(3):185-9. doi: 10.1097/ICU.0b013e3283459724. Review.

PMID:
21427573
10.

Anti-vascular endothelial growth factor agents for diabetic maculopathy.

Salam A, DaCosta J, Sivaprasad S.

Br J Ophthalmol. 2010 Jul;94(7):821-6. doi: 10.1136/bjo.2009.163576. Epub 2009 Jun 24. Review.

PMID:
19556214
11.

Selective and pan-blockade agents in the anti-angiogenic treatment of proliferative diabetic retinopathy: a literature summary.

Giuliari GP, Guel DA, Cortez MA, Cortez RT.

Can J Ophthalmol. 2010 Oct;45(5):501-8. doi: 10.3129/i10-023. Review.

PMID:
20648074
12.

Comparative effectiveness of anti-VEGF agents for diabetic macular edema.

Ollendorf DA, Colby JA, Pearson SD.

Int J Technol Assess Health Care. 2013 Oct;29(4):392-401. doi: 10.1017/S0266462313000500. Review.

PMID:
24290332
13.

Comparative effectiveness of anti-growth factor therapies for diabetic macular edema: summary of primary findings and conclusions.

O'Malley PG.

Arch Intern Med. 2012 Jul 9;172(13):1014-5. doi: 10.1001/archinternmed.2012.2335. Review. No abstract available.

PMID:
22688778
14.

Anti-VEGF therapeutic approaches for diabetic macular edema.

Khurana RN, Do DV, Nguyen QD.

Int Ophthalmol Clin. 2009 Spring;49(2):109-19. doi: 10.1097/IIO.0b013e31819fd8b5. No abstract available.

PMID:
19349791
15.

Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.

Zehetner C, Kirchmair R, Huber S, Kralinger MT, Kieselbach GF.

Br J Ophthalmol. 2013 Apr;97(4):454-9. doi: 10.1136/bjophthalmol-2012-302451. Epub 2013 Feb 5.

PMID:
23385630
16.

[Anti-VEGF inhibitors and their role in the treatment of diabetic macular oedema].

Kakkassery V, Winterhalter S, Joussen AM.

Klin Monbl Augenheilkd. 2010 Sep;227(9):701-11. doi: 10.1055/s-0029-1245718. Epub 2010 Sep 15. Review. German.

PMID:
20845250
17.

Vascular endothelial growth factor inhibitors (anti-VEGF) in the management of diabetic macular oedema: a systematic review.

Zechmeister-Koss I, Huic M.

Br J Ophthalmol. 2012 Feb;96(2):167-78. doi: 10.1136/bjophthalmol-2011-300674. Epub 2011 Dec 1. Review.

PMID:
22133986
18.

Anti-angiogenesis drugs in diabetic retinopathy.

Jeganathan VS.

Curr Pharm Biotechnol. 2011 Mar 1;12(3):369-72. Review.

PMID:
20939797
19.

Treatment of proliferative diabetic retinopathy with anti-VEGF agents.

Salam A, Mathew R, Sivaprasad S.

Acta Ophthalmol. 2011 Aug;89(5):405-11. doi: 10.1111/j.1755-3768.2010.02079.x. Epub 2011 Feb 5. Review.

20.

Treatment of diabetic retinopathy with anti-VEGF drugs.

Waisbourd M, Goldstein M, Loewenstein A.

Acta Ophthalmol. 2011 May;89(3):203-7. doi: 10.1111/j.1755-3768.2010.02010.x. Epub 2010 Nov 2. Review.

Items per page

Supplemental Content

Write to the Help Desk